Epistemic AI

Name: Epistemic AI
Brand: Epistemic AI

The next generation search engine for the life sciences. Explore and discover from hundreds of sources with AI.

Est 2018|Valuation $24M|Raised $11M|10 Ref Customers

LinkedIn 2K|Website|FTEs 29|HQ New York, New York, US

MarketsResearch Firms

Published Oct 1, 2026

01Common complaints

- If you need a heavily standardized, procurement-friendly vendor with publicly documented compliance - If organizational policy requires SOC 2 Type II, ISO 27001, or similar documentation to be publicly posted or quickly available, Epistemic AI’s public materials may not satisfy initial gating and private evidence may be required. - If you primarily need raw datasets and "source of truth" databases - Large organizations that already have mature intelligence stacks (such as Cortellis, Citeline/Norstella, IQVIA) may prefer to use established data platforms and layer AI capabilities on top. - If you require large volumes of workflow automation without any human validation bottleneck - Epistemic AI emphasizes expert validation; organizations that cannot support a review step may experience throughput limitations or increased latency. - If budget predictability and self-serve trials are critical - With no public list pricing and a consultative engagement model, teams with strict upfront budget constraints or a need for transparent pricing may prefer tools with published pricing. - If you need broad, cross-industry market intelligence - Epistemic AI is life-sciences-focused; for general market or cross-industry intelligence, broader platforms such as AlphaSense may be more appropriate. - Publicly observable limitations - Sparse independent review footprint makes it difficult to validate claims around: - Accuracy rates - Coverage breadth by therapeutic area - Reliability and uptime - Support responsiveness - Security/compliance disclosure gap - Public materials do not document SOC 2/ISO certifications, data residency, or enterprise identity and access management features. - Pricing opacity - Quote-based pricing increases procurement time and complicates competitive bake-offs. - Terminology ambiguity risk - "Epistemic AI" may also refer to unrelated initiatives (for example, an EU-funded research project with a similar name). Buyers should confirm they are evaluating Epistemic AI, Inc. (epistemic.ai) and not similarly named research initiatives.

Deal disqualifiers: what makes a POOR fit

Buyers that require publicly documented SOC 2 / ISO certifications before starting a pilot (unless Epistemic can provide such reports privately)
Teams expecting a self-serve, low-touch product with public pricing
Use cases that require guaranteed coverage of proprietary datasets unless Epistemic supports secure ingestion and governance (not publicly documented)

02Why they buy

- Evidence traceability and provenance emphasis - The vendor emphasizes that deliverables are grounded in identifiable primary sources (for example, regulatory filings, trial registries, and published literature) and that claim-level traceability is provided for audit purposes. - Multi-agent workflows packaged into strategic work products - The vendor offers automated workflows intended to produce recurring strategic documents and updates rather than only question-and-answer interactions. - Expert validation and services wrapper - The vendor describes a services-led delivery model in which life-science experts review outputs to support internal decision-making. - Caveat - These attributes are vendor-asserted and limited independent reviews were found to validate them; buyers should verify through pilots and references.

03Field reports

Customer Testimonials

- Important constraint: limited third-party review coverage - Epistemic AI does not appear to have a significant footprint on major review platforms (G2, TrustRadius, Gartner Peer Insights) in the sources accessible during this research. - This limits the ability to triangulate customer sentiment at scale; most available testimonials are vendor-published quotes and vendor-authored success narratives. - Official/vendor-published testimonial (attributed quote) - From Epistemic AI’s EpistemicGPT workbook page: - "The Epistemic AI platform is an important journey. It provides a way to easily validate any hypothesis while saving time and critical resources." — Pratip Chattopadhyay, PhD, Former Director, Applied Immunology Core, NYU Langone - Interpretation: the quote asserts time and resource savings and that the platform supports hypothesis validation; it is vendor-published and not independently audited. - Community discussion mention (contextual, not a product review) - In a Hacker News thread (Aug 8, 2021), a commenter identifying as a co-founder stated: "The company I co-founded, Epistemic AI, was built to accelerate biomedical research especially in rare diseases and cancers." - This is not a third-party review, but it indicates early positioning and founder outreach. - Gartner Peer Insights / G2 / TrustRadius - No accessible Epistemic AI review listings were found on Gartner Peer Insights, G2, or TrustRadius in the searches performed. - What buyers should infer from the lack of reviews - Potentially early-stage category fit, an enterprise buyer base that does not publish public reviews, or low visibility on review platforms. - Higher diligence burden on reference checks, pilots, and contractual acceptance criteria.

Vendor-published case narratives (examples)

#### Automating Target Product Profiles (anonymized large pharma customer) - Vendor assertion: substantially reduced manual TPP work using an automated TPP engine; expanded from a pilot into a multi-phase integration. - Critical evaluation: - No quantitative before/after metrics (e.g., time saved, cost, error rates) are provided. - The vendor states outputs were "validated by experts," but the validation methodology is not disclosed. #### Scaling conference intelligence across multiple conferences (anonymized global pharma RWE team) - Vendor assertion: automated extraction, classification, and thematic analysis of abstracts; delivered structured intelligence including key messages and evidence gaps. - Critical evaluation: - Baseline performance issues (for example, classification quality) are described, but no measured improvements (precision/recall or equivalent) are provided. - Output quality likely depends on taxonomy definitions and subject-matter expert review; buyers should request sample deliverables. #### Regulatory and RWE intelligence at scale - Vendor assertion: platform generated regulatory update analyses and HTA-ready deliverables; engagement expanded from proof-of-concept to an ongoing partnership. - Critical evaluation: - The term "HTA-ready" is a high bar; no independent verification or named customer was provided. #### Replacing manual conference analysis (public biotech) - Vendor assertion: automated conference intelligence including SWOT analyses and identification of competitive mentions at a lower cost relative to consultants. - Critical evaluation: - The vendor's cost comparison is not quantified; outcomes depend heavily on what is counted as cost (subscriptions vs consulting hours).

Bottom line on case narratives

The vendor-published case narratives illustrate plausible use cases but lack disclosed methodology, sample size, or third-party validation.
Buyers should require named references or reference calls, side-by-side comparisons versus prior processes, and acceptance criteria tied to accuracy, completeness, and traceability.

04Best fit

Company sizes

Best inferred fit: mid-market through large pharmaceutical/biotech organizations where competitive intelligence and strategy teams exist and the cost of incorrect decisions is high (e.g., organizations with established CI functions and cross-functional strategy groups).
Smaller biotechs may also fit if they frequently outsource strategy deliverables to consultants and can justify a platform/project alternative.

Industries and verticals

Biopharma / biotech
Potential adjacency: life sciences consulting groups supporting multiple clients (subject to licensing terms)

Roles and personas

Decision makers
- Head of Competitive Intelligence
- VP/Director of Portfolio Strategy / Corporate Strategy
- Medical affairs leadership
- RWE / Market Access leads
End users
- CI analysts
- Strategy & planning managers
- Medical/scientific communications staff involved in congress coverage

Pain points and challenges the product addresses

High manual workload for landscapes and target product profiles (TPPs)
Need to process large volumes of conference content
Requirement for traceability and evidence links in a regulated, evidence-driven domain
Desire to reduce reliance on consulting cycles for recurring strategic artifacts

Qualification criteria: what makes a GOOD fit

Teams that repeatedly create the same strategic artifacts across multiple indications
Organizations that can operationalize a human review loop with SME reviewers
Companies that value traceability and defensibility of claims for internal governance

05The pitch

What the product does (core value proposition in objective terms)

- Epistemic AI offers a life-sciences strategic intelligence platform that automates recurring drug-development strategy deliverables (for example, competitive landscapes, Target Product Profiles (TPPs), and conference intelligence) using a multi-agent system (referred to by the vendor as "EpistemicGPT") built on a proprietary biomedical knowledge graph. - The vendor states the platform is intended to reduce turnaround time for these deliverables (days vs. weeks/months) while producing outputs that are linked to evidence and are reviewable for provenance and auditability, with human validation as part of the workflow.

Target market and market positioning

- Primary buyers/users (as described by the vendor) appear to be biopharma teams spanning: - Corporate strategy / portfolio planning - Competitive intelligence - Medical affairs - Real-world evidence (RWE) and market access teams - The vendor positions the product as an alternative to manual intelligence gathering and parts of some consulting engagements, combining a continuously available platform with expert services to produce recurring strategic deliverables.

Get a comprehensive analysis of Epistemic AI including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →